局部晚期宫颈癌免疫治疗进展  

Advances in immunotherapy for locally advanced cervical cancer

作　　者：王孟菲(综述) 许波群(审校)[1] WANG Mengfei;XU Boqun(Department of Obstetrics and Gynecology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing 210000,China)

机构地区：[1]南京医科大学第二附属医院妇产科,南京210000

出　　处：《实用肿瘤学杂志》2025年第2期157-161,共5页Practical Oncology Journal

摘　　要：早期宫颈癌可以通过手术治愈,但约有一半的患者在初诊时已是局部晚期,以顺铂为基础的同步放化疗是治疗局部晚期宫颈癌的标准方案。然而,在完成同步放化疗后,这些患者的预后仍然较差。免疫治疗的出现极大地改善了晚期和复发性宫颈癌患者的预后,正逐步与化疗、放疗和靶向治疗等常规治疗结合。近期的研究显示,帕博利珠单抗联合同步放化疗明显提高了局部晚期宫颈癌患者无进展生存率,且未明显增加毒副反应的发生率;新辅助化疗联合免疫检查点抑制剂治疗与手术相结合有望成为治疗局部晚期宫颈癌的新方案;在同步放化疗后使用纳武利尤单抗免疫维持治疗可能会提高局部晚期宫颈癌患者的生存率并改善治疗效果。本文对局部晚期宫颈癌免疫治疗进展进行了综述。Early cervical cancer can be cured through surgery,but about half of patients are already locally advanced at the time of initial diagnosis.Cisplatin-based concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer.However,the prognosis of these patients remains poor after completing simultaneous radiotherapy and chemotherapy.The emergence of immunotherapy has dramatically improved the prognosis of patients with advanced and recurrent cervical cancer,and is gradually being combined with conventional treatments such as chemotherapy,radiotherapy and targeted therapy.Recent studies have shown that the combination of pembrolizumab and concurrent radiotherapy significantly improves the progression-free survival rate of patients with lo-cally advanced cervical cancer,without significantly increasing the incidence of toxic side effects;The combination of neoadjuvant chemotherapy with immune checkpoint inhibitors and surgery is expected to become a new treatment option for locally advanced cervi-cal cancer;The use of nabumolizumab immunomaintenance therapy after synchronous radiotherapy and chemotherapy may improve the survival rate and treatment efficacy of patients with locally advanced cervical cancer.This article provides a review of the progress in immunotherapy for locally advanced cervical cancer.

关 键 词：局部晚期宫颈癌 同步放化疗 免疫检查点抑制剂 不良事件 

分 类 号：R737.33[医药卫生—肿瘤]